Pharmacological Management of Coagulation

The anticoagulant activity of unfractionated heparin resides in a specific pentasaccharide sequence present in approximately one-third of heparin molecules. This pentasaccharide binds to antithrombin III, inducing a conformational change that exposes its reactive site loop and converts antithrombin III from a slow, progressive inhibitor to a rapid inhibitor of coagulation serine proteases. The accelerated antithrombin III inhibits thrombin (factor IIa) and factor Xa with roughly equal potency, as well as factors IXa, XIa, and XIIa to a lesser degree.

For thrombin inhibition, heparin must simultaneously bind both antithrombin III and thrombin, forming a ternary complex. This bridging requirement means that only heparin chains of at least 18 saccharide units can inhibit thrombin. For factor Xa inhibition, the pentasaccharide sequence alone is sufficient without bridging — which is why shorter heparin fragments retain anti-factor Xa activity but not anti-thrombin activity. This molecular length distinction is the pharmacological basis for the difference between unfractionated heparin and the low-molecular-weight heparins.

Unfractionated heparin pharmacokinetics are governed by two simultaneous clearance mechanisms: a rapid, saturable, dose-dependent mechanism mediated by binding to endothelial cells and macrophages, and a slower, first-order renal clearance mechanism. At low doses, the saturable cellular clearance pathway dominates, producing a short apparent half-life of approximately 30 minutes. At higher doses, the cellular pathway saturates and the half-life extends to 60 to 90 minutes. This dose-dependent nonlinearity means that doubling the dose produces a greater-than-proportional increase in anticoagulant effect — making weight-based dosing with activated partial thromboplastin time-guided adjustment mandatory for therapeutic anticoagulation.

Unfractionated heparin binds extensively and non-specifically to a large number of plasma proteins beyond antithrombin III, including platelet factor 4, fibronectin, vitronectin, and acute-phase reactant proteins. Only the fraction not bound to these non-antithrombin III proteins is pharmacologically active, and this fraction varies substantially between patients — particularly in inflammatory states where elevated platelet factor 4 (released from activated platelets) reduces heparin availability. This nonspecific protein binding underlies the well-documented interpatient variability in activated partial thromboplastin time response to fixed heparin doses and the phenomenon of heparin resistance.

Unfractionated heparin is administered intravenously for therapeutic anticoagulation in acute settings, or subcutaneously for prophylaxis. Intravenous unfractionated heparin provides immediate anticoagulation; subcutaneous unfractionated heparin has a delayed onset of one to two hours and reduced bioavailability at prophylactic doses. The standard approach to therapeutic intravenous anticoagulation uses a weight-based nomogram: a bolus of 80 units per kilogram followed by an infusion of 18 units per kilogram per hour, with subsequent activated partial thromboplastin time-guided adjustment to a target of 60 to 100 seconds. Unfractionated heparin requires no dose adjustment for renal impairment, making it the preferred anticoagulant in patients with severe acute kidney injury where low-molecular-weight heparins would accumulate.

Two distinct syndromes carry the name heparin-induced thrombocytopenia. Type I (heparin-associated thrombocytopenia) is a non-immune, direct pharmacological effect of heparin on platelets, occurring in up to 10% of patients receiving unfractionated heparin within the first one to two days. It produces a mild, transient platelet count decrease that resolves spontaneously without any change in therapy and carries no thrombosis risk. No specific intervention is required.

Type II heparin-induced thrombocytopenia is a distinct immune-mediated syndrome caused by antibodies to a complex of platelet factor 4 and heparin. It occurs in 0.1 to 5% of heparin-exposed patients (higher incidence with unfractionated heparin than low-molecular-weight heparin; lowest with fondaparinux), typically develops 5 to 14 days after heparin initiation, and is associated with a 20 to 50% risk of thrombosis. All subsequent use of the term heparin-induced thrombocytopenia in this module refers to Type II.

Heparin, a polyanion, forms an electrostatic complex with platelet factor 4, a polycation released from platelet alpha-granules. This complex creates a neo-antigen recognized as foreign by the immune system. In susceptible individuals, immunoglobulin G antibodies against the platelet factor 4-heparin complex are generated within 5 to 14 days of exposure. These antibodies have two pathological consequences: the immunoglobulin G Fc region cross-links Fc-gamma receptor IIA on platelet surfaces, activating platelets and triggering further platelet factor 4 release and procoagulant microparticle generation; simultaneously the immune complex binds monocytes and endothelial cells, generating tissue factor expression and amplifying thrombin generation. The result is a massively prothrombotic state despite thrombocytopenia — explaining the counterintuitive syndrome of falling platelet count with increasing clot formation. Even heparin catheter flushes at doses of 10 to 100 units are sufficient to sustain the prothrombotic process once antibodies are present.

The classic presentation is a platelet count fall of 50% or more from baseline occurring 5 to 14 days after heparin initiation, in association with thrombosis or thromboembolic complications. Both venous thrombosis (deep vein thrombosis, pulmonary embolism) and arterial thrombosis (limb ischemia, stroke) occur; venous is more common. Limb gangrene in the setting of a falling platelet count on heparin is a medical emergency.

The 4T score is the validated pretest probability tool for heparin-induced thrombocytopenia, assigning points across four categories: Thrombocytopenia (magnitude and pattern of platelet fall), Timing (onset relative to heparin exposure), Thrombosis (presence and type), and other causes of Thrombocytopenia (absence of alternative explanations). A score of 0 to 3 indicates low probability, with a negative predictive value exceeding 99%, effectively ruling out heparin-induced thrombocytopenia and permitting continued heparin use. A score of 4 to 5 indicates intermediate probability — heparin should be discontinued and laboratory testing initiated. A score of 6 to 8 indicates high probability — heparin must be stopped immediately and empirical alternative anticoagulation initiated before laboratory results are available.

Laboratory confirmation requires either an immunological or a functional assay. The enzyme-linked immunosorbent assay for anti-platelet factor 4-heparin immunoglobulin G antibodies is highly sensitive (greater than 95%) but has lower specificity, as platelet factor 4-heparin antibodies can be generated in up to 50% of patients after cardiac surgery without causing clinical heparin-induced thrombocytopenia. The serotonin release assay, considered the gold standard functional test, measures whether patient plasma activates normal donor platelets in the presence of therapeutic concentrations of heparin; a positive result (greater than 20% serotonin release) confirms platelet-activating antibodies with specificity exceeding 95%. Because the serotonin release assay is technically demanding and not widely available, the enzyme-linked immunosorbent assay is the practical first-line test.

For venous thromboembolism prophylaxis in surgical patients, subcutaneous unfractionated heparin at 5,000 units every 8 to 12 hours and subcutaneous enoxaparin at 40 mg once daily are equivalent options. For high-risk orthopedic surgery, extended prophylaxis for 10 to 35 days with low-molecular-weight heparin or fondaparinux is guideline-recommended; fondaparinux demonstrated superior venous thromboembolism prevention compared to enoxaparin in major orthopedic surgery trials but carries higher bleeding risk and lacks a reversal agent.

For treatment of acute deep vein thrombosis and pulmonary embolism, low-molecular-weight heparin has been demonstrated non-inferior to unfractionated heparin and is the preferred initial anticoagulant for most patients treated outside the intensive care unit setting. Unfractionated heparin retains first-line status for massive pulmonary embolism with hemodynamic instability (where thrombolysis may be immediately required and unfractionated heparin can be rapidly reversed with protamine), for pulmonary embolism with severe renal impairment, and in intensive care unit settings requiring frequent dose adjustment. Low-molecular-weight heparin (dalteparin) is preferred over warfarin for cancer-associated venous thromboembolism, where it reduces recurrence more effectively.

In acute coronary syndrome, parenteral anticoagulation with unfractionated heparin, enoxaparin, fondaparinux, or bivalirudin is used during the acute phase and during percutaneous coronary intervention. Fondaparinux demonstrated superior net clinical outcomes compared to enoxaparin in a large acute coronary syndrome trial but is associated with catheter thrombosis during percutaneous coronary intervention if used as the sole anticoagulant, requiring supplemental unfractionated heparin for the procedure.

Bridging anticoagulation refers to use of a short-acting parenteral anticoagulant to cover the perioperative period when long-term oral anticoagulation is interrupted for surgery. Low-molecular-weight heparin at therapeutic doses is the standard bridging agent. However, for most patients with atrial fibrillation and moderate stroke risk, a large randomized trial demonstrated that forgoing bridging anticoagulation was non-inferior to low-molecular-weight heparin bridging for preventing thromboembolism while significantly reducing perioperative bleeding. Current guidelines therefore recommend against routine bridging in most atrial fibrillation patients, reserving it for patients at very high thromboembolic risk — mechanical heart valves, recent stroke, or recent venous thromboembolism within 3 months.